oregon psilocybin

Oregon Psilocybin: Preparing for the End of Local Ownership Rules

Oregon’s rule limiting the non-resident ownership of licensed psilocybin businesses sunsets on December 31, 2024. That’s a little over six months away. Six months is not that long, especially in the context of getting to know an industry or a business, and putting a thoughtful deal together– one that will generate reasonable returns for an

oregon

Oregon Ketamine Clinics: New Potential Restrictions on Corporate Practice of Medicine

Should private equity be involved in health care? If so, in what types of settings? And to what extent? These are baseline considerations around a broad concept referred to as “corporate practice of medicine” (“CPOM”) that state legislatures, agencies, medical licensing boards, courts and attorneys general and grappled with for over a century. The Oregon

hall of shame

The Psychedelics Company Structure Hall of Shame (with Pictures)

The Oregon psilocybin program has a residency requirement. I explained how it works here, and wrote “queue the crazy business structures.” Because the program is off to a slow start (see here and here) I haven’t received as many crazy requests as expected. Well, that changed last week when I received a proposal that made

psilocybin securities

Oregon Psilocybin and Securities: Raising Money Right

Oregon psilocybin licensing kicks off in just over a month. We are finally in the home stretch of the two-year run-up following the passage of Measure 109. At this point, many people are forming psilocybin businesses and raising money for these new ventures. What’s old is new again We went through similar business structuring and

Ketamine Clinic Acquisitions: Get the Law Right BEFORE the LOI

Ketamine Clinic Acquisitions: Get the Law Right BEFORE the LOI

We often receive calls from potential ketamine clinic clients that just signed a letter of intent (“LOI”) or term sheet to acquire entire medical practices that are undertaking ketamine treatments. In the psychedelics space, many companies are starting off with off-label ketamine treatments while building towards a bigger suite of psychedelic services as the laws

stock market public company psychedelics

Psychedelics, Cannabis and the Stock Exchanges

Last week, I came across an article surveying the 50 (!) psychedelics companies that are now publicly traded on U.S. exchanges— a handful of which we are proud to call our clients. Of these, 41 are listed on over the counter (OTC) markets, while the remaining nine outfits are traded on either the Nasdaq or

ketamine clinic joint venture aks hhs audit

Ketamine Clinics and Joint Ventures: The Office of Inspector’s Concerns

As the economy continues to flourish, there is a proliferation of merger and acquisition activity in the healthcare space. We continue to see a rise in ketamine clinic acquisitions as well as investors who are starting management services organizations (“MSO”) to assist such clinics with their administrative burden. Likewise, we have seen an increase in

MDMA Ecstasy fda maps

MDMA (Ecstasy) Nears FDA Approval for PTSD Treatment

Efforts by the Multidisciplinary Association for Psychedelic Studies (MAPS) to legalize prescription MDMA (Ecstasy) appear to have passed a gigantic hurdle earlier this month: MDMA is on track to meet the testing requirements to be a legalized prescription drug, specifically intended to treat the symptoms of post-traumatic stress disorder (PTSD). After analyzing the preliminary results